A Phase I Study of ICP-022 in Healthy Subjects

NCT03189017 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus
Rheumatoid Arthritis

Interventions

DRUG: ICP-022
DRUG: Placebos

Sponsor

Innocare Pharma Australia Pty Ltd